Remember the “Fatty Fifty” for Lipid Levels

The novel triple fixed-dose combination of telmisartan, amlodipine and indapamide, is the first of its kind approved for initial treatment of hypertension.

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Adults with both HTN and T2D had more than twice the risk of all-cause mortality and nearly three times the risk of cardiovascular mortality, according to new data.

Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.

ESOC 2025: New research reveals that combined oral contraceptive use significantly increases the risk of cryptogenic stroke in young women, urging careful assessment by clinicians.

Semaglutide was associated with a significant reduction in risk for major adverse cardiovascular events after just 3 months of treatment in a population with established CVD.